::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

EXPEDIENCY AND PRACTICALITY OF ACCUMULATION OF PEG-IFN-𝛼-2A TO ENTECAVIR IN ADDITION WITH A VIEW TO DISCONTINUING ENTECAVIR

AUTHORS:

Dr Ayesha Munawar, Dr Sehreen Anmber, Dr M Raza

ABSTRACT:

Our current research was conducted at Mew Hospital, Lahore from December 2017 to November 2018. Entecavir needs long standing organization. Treatment with pegylated interferon results in a substantial decrease in hepatitis B surface antigen (HBs Ag) levels. The current review should investigate the well-being and viability of adding PEG-IFN-𝛼-2a to entecavir with a view to discontinuing entecavir. The overall of 26 cases cured through entecavir received additional treatment with PEG-IFN-𝛼-2a (90 𝜇g each week) for 49 weeks. The viral reaction (VR) was characterized by a decrease of more than half of the baseline hepatitis B surface antigen (HBs Ag) level at 72 weeks from the start of treatment. The complete reaction (CR) was characterized by decreased levels of HBs Ag <100 IU/mL. The hepatitis B e antigen (HBe Ag) serocon version rate was 25% (2/8), and the VR rate remained 53% (12/23). An OR was observed in four cases (17%). Though, the CR degree in baseline cases with HBsAg <2000 IU/mL and HBeAg-negative cases was half (4/8). The univariate examination indicated that the decrease in HBs Ag at week 12 was primarily related to VR. The area underneath elbow remained 0.849. The addition of PEG-IFN-𝛼-2a to entecavir limited viability. The drop in HBs Ag at week 13might be the valuable indicator for VR.